Application 125545
- Type
- BLA
- Sponsor
- HOSPIRA INC
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 125545 | Retacrit | epoetin alfa-epbx | 351(k) Biosimilar | Rx | 2026-07-01 |
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | RETACRIT | EPOETIN ALFA-EPBX | INJECTABLE;INJECTION | 2,000UNITS/ML | No | No |
| 002 | RETACRIT | EPOETIN ALFA-EPBX | INJECTABLE;INJECTION | 3,000UNITS/ML | No | No |
| 003 | RETACRIT | EPOETIN ALFA-EPBX | INJECTABLE;INJECTION | 4,000UNITS/ML | No | No |
| 004 | RETACRIT | EPOETIN ALFA-EPBX | INJECTABLE;INJECTION | 10,000UNITS/ML | No | No |
| 005 | RETACRIT | EPOETIN ALFA-EPBX | INJECTABLE;INJECTION | 40,000UNITS/ML | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| RETACRIT | EPOETIN ALFA-EPBX | Vifor (International) Inc. | e6e4dd0c-25ca-40b2-ba6b-6138a68621fe | 2025-06-22 | Boxed warning, Warnings, Adverse reactions | BLA125545 59353-002 59353-003 59353-004 59353-010 |
| RETACRIT | EPOETIN ALFA-EPBX | Pfizer Laboratories Div Pfizer Inc | 3af26b0d-8ad0-44e1-a538-8bdb5ab39374 | 2025-06-22 | Boxed warning, Warnings, Adverse reactions | BLA125545 0069-1308 0069-1307 0069-1306 0069-1305 0069-1318 0069-1309 0069-1311 |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1305 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1306 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1307 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1308 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1309 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1311 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1311 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1311 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1318 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1318 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 0069-1318 | RETACRIT | epoetin alfa-epbx | Pfizer Laboratories Div Pfizer Inc | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-002 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-003 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-004 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-010 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
| 59353-010 | RETACRIT | epoetin alfa-epbx | Vifor (International) Inc. | BLA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 78649 | SUPPL | 2024-06-05 |
| 78648 | SUPPL | 2024-06-05 |
| 78635 | SUPPL | 2024-06-05 |
| 74025 | SUPPL | 2023-04-20 |
| 74024 | SUPPL | 2023-04-19 |
| 63771 | SUPPL | 2020-07-01 |
| 63765 | SUPPL | 2020-07-01 |
| 63764 | SUPPL | 2020-07-01 |
| 57298 | SUPPL | 2019-01-22 |
| 57288 | SUPPL | 2019-01-22 |
| 57287 | SUPPL | 2019-01-22 |
| 56726 | ORIG | 2018-12-13 |
| 54190 | ORIG | 2018-05-15 |
| 54187 | ORIG | 2018-05-15 |
| 54186 | ORIG | 2018-05-15 |